The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
Seventh Sense Biosystems markets a one-step, push-button device called Tap that uses a microneedle array to collect capillary blood from the arm.
The firm's CEO said it is continuing to develop its distributor network to make its tests available in centralized and decentralized settings globally.
McKesson will be the exclusive distributor of the QiaStat-Dx system in US hospitals with fewer than 200 beds and non-exclusive distributor for future expansion into retail pharmacy clinics.
The test, called EZ Detect, is a flushable pad that detects the presence of fecal occult blood when dropped into a toilet following a bowel movement.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
SensID specializes in the development, manufacture, and marketing or reference materials and quality controls for DNA-based diagnostics.
LabCorp will further invest in OmniSeq as part of the deal, which covers distribution of the latter's immune profiling and pan-cancer next-generation sequencing tests.
HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.
Orto+ will be market and distribute Todos' TM-B2 test for breast cancer screening in Romania and Austria. The test is CE marked.